Literature DB >> 27375010

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

F Theis1, A Corbacioglu1, V I Gaidzik1, P Paschka1, D Weber1, L Bullinger1, M Heuser2, A Ganser2, F Thol2, B Schlegelberger3, G Göhring3, C-H Köhne4, U Germing5, P Brossart6, H-A Horst7, D Haase8, K Götze9, M Ringhoffer10, W Fiedler11, D Nachbaur12, T Kindler13, G Held14, M Lübbert15, M Wattad16, H R Salih17, J Krauter18, H Döhner1, R F Schlenk1, K Döhner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27375010     DOI： 10.1038/leu.2016.185

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.

Authors:  Philipp A Greif; Annika Dufour; Nikola P Konstandin; Bianka Ksienzyk; Evelyn Zellmeier; Belay Tizazu; Jutta Sturm; Tobias Benthaus; Tobias Herold; Marjan Yaghmaie; Petra Dörge; Karl-Peter Hopfner; Andreas Hauser; Alexander Graf; Stefan Krebs; Helmut Blum; Purvi M Kakadia; Stephanie Schneider; Eva Hoster; Friederike Schneider; Martin Stanulla; Jan Braess; Maria Cristina Sauerland; Wolfgang E Berdel; Thomas Büchner; Bernhard J Woermann; Wolfgang Hiddemann; Karsten Spiekermann; Stefan K Bohlander
Journal:  Blood       Date:  2012-05-30       Impact factor: 22.113

2.  A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML.

Authors:  Bas J Wouters; Irene Louwers; Peter J M Valk; Bob Löwenberg; Ruud Delwel
Journal:  Blood       Date:  2007-01-01       Impact factor: 22.113

3.  GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.

Authors:  A Fasan; C Eder; C Haferlach; V Grossmann; A Kohlmann; F Dicker; W Kern; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2012-07-03       Impact factor: 11.528

4.  Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Authors:  Erdogan Taskesen; Lars Bullinger; Andrea Corbacioglu; Mathijs A Sanders; Claudia A J Erpelinck; Bas J Wouters; Sonja C van der Poel-van de Luytgaarde; Frederik Damm; Jürgen Krauter; Arnold Ganser; Richard F Schlenk; Bob Löwenberg; Ruud Delwel; Hartmut Döhner; Peter J M Valk; Konstanze Döhner
Journal:  Blood       Date:  2010-12-21       Impact factor: 22.113

5.  Interaction between GATA and the C/EBP family of transcription factors is critical in GATA-mediated suppression of adipocyte differentiation.

Authors:  Qiang Tong; Judy Tsai; Guo Tan; Gökhan Dalgin; Gökhan S Hotamisligil
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

6.  Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.

Authors:  R F Schlenk; S Fröhling; F Hartmann; J Th Fischer; A Glasmacher; F del Valle; W Grimminger; K Götze; C Waterhouse; R Schoch; H Pralle; H G Mergenthaler; M Hensel; E Koller; H Kirchen; J Preiss; H Salwender; H G Biedermann; S Kremers; F Griesinger; A Benner; B Addamo; K Döhner; R Haas; H Döhner
Journal:  Leukemia       Date:  2004-11       Impact factor: 11.528

7.  Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.

Authors:  R F Schlenk; A Benner; F Hartmann; F del Valle; C Weber; H Pralle; J Th Fischer; U Gunzer; A Pezzutto; W Weber; W Grimminger; J Preiss; M Hensel; S Fröhling; K Döhner; R Haas; H Döhner
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

Review 8.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

9.  An early haematopoietic defect in mice lacking the transcription factor GATA-2.

Authors:  F Y Tsai; G Keller; F C Kuo; M Weiss; J Chen; M Rosenblatt; F W Alt; S H Orkin
Journal:  Nature       Date:  1994-09-15       Impact factor: 49.962

10.  Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Christopher N Hahn; Chan-Eng Chong; Catherine L Carmichael; Ella J Wilkins; Peter J Brautigan; Xiao-Chun Li; Milena Babic; Ming Lin; Amandine Carmagnac; Young K Lee; Chung H Kok; Lucia Gagliardi; Kathryn L Friend; Paul G Ekert; Carolyn M Butcher; Anna L Brown; Ian D Lewis; L Bik To; Andrew E Timms; Jan Storek; Sarah Moore; Meryl Altree; Robert Escher; Peter G Bardy; Graeme K Suthers; Richard J D'Andrea; Marshall S Horwitz; Hamish S Scott
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330
  10 in total
  16 in total

Review 1.  The GATA factor revolution in hematology.

Authors:  Koichi R Katsumura; Emery H Bresnick
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

2.  Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA.

Authors:  Feng-Ming Tien; Hsin-An Hou; Jih-Luh Tang; Yuan-Yeh Kuo; Chien-Yuan Chen; Cheng-Hong Tsai; Ming Yao; Chien-Ting Lin; Chi-Cheng Li; Shang-Yi Huang; Bor-Sheng Ko; Szu-Chun Hsu; Shang-Ju Wu; Jia-Hau Liu; Sheng Chieh Chou; Woei Tsay; Mei-Hsuan Tseng; Ming-Chih Liu; Chia-Wen Liu; Liang-In Lin; Wen-Chien Chou; Hwei-Fang Tien
Journal:  Haematologica       Date:  2018-05-17       Impact factor: 9.941

3.  Phenotypic heterogeneity associated with germline GATA2 haploinsufficiency: a comprehensive kindred study.

Authors:  Candace L Haddox; Ryan M Carr; Roshini S Abraham; Juliana Perez Botero; Vilmarie Rodriguez; Animesh Pardanani; Mrinal M Patnaik
Journal:  Leuk Lymphoma       Date:  2019-06-27

4.  Human leukemia mutations corrupt but do not abrogate GATA-2 function.

Authors:  Koichi R Katsumura; Charu Mehta; Kyle J Hewitt; Alexandra A Soukup; Isabela Fraga de Andrade; Erik A Ranheim; Kirby D Johnson; Emery H Bresnick
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-09       Impact factor: 11.205

5.  CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.

Authors:  Katherine Tarlock; Adam J Lamble; Yi-Cheng Wang; Robert B Gerbing; Rhonda E Ries; Michael R Loken; Lisa Eidenschink Brodersen; Laura Pardo; Amanda Leonti; Jenny L Smith; Tiffany A Hylkema; William G Woods; Todd M Cooper; E Anders Kolb; Alan S Gamis; Richard Aplenc; Todd A Alonzo; Soheil Meshinchi
Journal:  Blood       Date:  2021-09-30       Impact factor: 25.476

Review 6.  Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes.

Authors:  Sushree S Sahoo; Emilia J Kozyra; Marcin W Wlodarski
Journal:  Best Pract Res Clin Haematol       Date:  2020-07-29       Impact factor: 3.020

7.  GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia.

Authors:  Feng-Ming Tien; Hsin-An Hou; Cheng-Hong Tsai; Jih-Luh Tang; Yu-Chiao Chiu; Chien-Yuan Chen; Yuan-Yeh Kuo; Mei-Hsuan Tseng; Yen-Ling Peng; Ming-Chih Liu; Chia-Wen Liu; Xiu-Wen Liao; Liang-In Lin; Chien-Ting Lin; Shang-Ju Wu; Bor-Sheng Ko; Szu-Chun Hsu; Shang-Yi Huang; Ming Yao; Wen-Chien Chou; Hwei-Fang Tien
Journal:  Blood Cancer J       Date:  2018-08-31       Impact factor: 11.037

Review 8.  Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?

Authors:  Emery H Bresnick; Mabel M Jung; Koichi R Katsumura
Journal:  Blood Adv       Date:  2020-09-22

9.  Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment.

Authors:  Dima El-Sharkawi; Duncan Sproul; Christopher G Allen; Andrew Feber; Melissa Wright; Robert K Hills; David C Linch; Rosemary E Gale
Journal:  Haematologica       Date:  2017-10-12       Impact factor: 9.941

10.  Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significance.

Authors:  Long Su; YeHui Tan; Hai Lin; XiaoLiang Liu; Li Yu; YanPing Yang; ShanShan Liu; Ou Bai; Yan Yang; FengYan Jin; JingNan Sun; ChunShui Liu; QiuJu Liu; SuJun Gao; Wei Li
Journal:  Oncotarget       Date:  2018-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.